Natco Pharma Stock Falls After FDA Inspection

  Published 9 months ago

Natco Pharma shares drop 2% after FDA notes procedural observation at Hyderabad facility, down 36% year to date.

  • U.S. FDA inspection of Hyderabad plant raises concerns with one procedural observation.
  • The company is confident in addressing FDA issues comprehensively, but no details have been disclosed.
  • Stock averages 'hold' rating, median price target at 935.50 rupees.
You might like these

India's RBI to Use CRR More Frequently for Liquidity Management

Castrol India Shares Jump on Potential Sale

Trent Shares Drop 7% Amid Growth Concerns

Orient Cement Stock Plummets 16.3% Amid Oversold Signals

Gold Surges as Tariffs & Uncertainty Rise

India HPI Growth Slows to 3.1% in Q4 2024-25

Ola Electric Launches MoveOS 5 for Enhanced EV Performance

News that matters the most ⚡